| __timestamp | Arrowhead Pharmaceuticals, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 79435000 |
| Thursday, January 1, 2015 | 57410147 | 162644000 |
| Friday, January 1, 2016 | 41454452 | 237939000 |
| Sunday, January 1, 2017 | 31690298 | 168435000 |
| Monday, January 1, 2018 | 52968505 | 173797000 |
| Tuesday, January 1, 2019 | 81048686 | 113842000 |
| Wednesday, January 1, 2020 | 128874979 | 747027000 |
| Friday, January 1, 2021 | 206342000 | 2534508000 |
| Saturday, January 1, 2022 | 297307000 | 1235278000 |
| Sunday, January 1, 2023 | 353188000 | 737502000 |
| Monday, January 1, 2024 | 505870000 |
Cracking the code
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Arrowhead Pharmaceuticals, Inc. and Novavax, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Novavax's R&D expenses surged by over 900%, peaking in 2021 with a staggering 2.5 billion dollars, driven by their pivotal role in COVID-19 vaccine development. In contrast, Arrowhead Pharmaceuticals exhibited a steady growth trajectory, with a 2,100% increase in R&D spending, reaching its highest in 2024. This consistent investment underscores Arrowhead's long-term strategy in RNA interference therapeutics. Notably, 2024 data for Novavax is missing, highlighting potential shifts in their strategic focus. As the biotech landscape continues to evolve, these spending patterns offer valuable insights into each company's innovation priorities.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Arrowhead Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Johnson & Johnson and Novavax, Inc.
Research and Development Investment: AstraZeneca PLC vs Novavax, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Opthea Limited vs Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Axsome Therapeutics, Inc. vs Novavax, Inc.
Research and Development Investment: Perrigo Company plc vs Novavax, Inc.
Analyzing R&D Budgets: Veracyte, Inc. vs Arrowhead Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Bausch Health Companies Inc. and Arrowhead Pharmaceuticals, Inc.